N-((2-oxo-4-phenethyl-3-(thiazol-2-yl)-1,2-dihydroquinolin-6-yl)methyl)-3-phenylpropanamide | 1259392-29-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-((2-oxo-4-phenethyl-3-(thiazol-2-yl)-1,2-dihydroquinolin-6-yl)methyl)-3-phenylpropanamide
• 英文别名: N-[[2-oxo-4-(2-phenylethyl)-3-(1,3-thiazol-2-yl)-1H-quinolin-6-yl]methyl]-3-phenylpropanamide
• CAS: 1259392-29-4
• 化学式: C₃₀H₂₇N₃O₂S
• 分子量: 493.629
• InChiKey: PFISNTYZWRKRES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  36
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  99.3
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  6-(aminomethyl)-4-phenethyl-3-(thiazol-2-yl)quinolin-2(1H)-one 、 3-苯丙酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-((2-oxo-4-phenethyl-3-(thiazol-2-yl)-1,2-dihydroquinolin-6-yl)methyl)-3-phenylpropanamide
  参考文献：
  名称：

  Discovery of novel quinolinone adenosine A2B antagonists

  摘要：

  A novel series of quinolinone-based adenosine A(2B) receptor antagonists was identified via high throughput screening of an encoded combinatorial compound collection. Synthesis and assay of a series of analogs highlighted essential structural features of the initial hit. Optimization resulted in an A2B antagonist (2i) which exhibited potent activity in a cAMP accumulation assay (5.1 nM) and an IL-8 release assay (0.4 nM). (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.10.030

文献信息

• Discovery of novel quinolinone adenosine A2B antagonists
  作者：Brian F. McGuinness、Koc-Kan Ho、Tara M. Stauffer、Laura L. Rokosz、Neelima Mannava、Steven G. Kultgen、Kurt Saionz、Anthony Klon、Weiqing Chen、Hema Desai、W. Lynn Rogers、Maria Webb、Juxing Yin、Yan Jiang、Tailong Li、Hao Yan、Konghua Jing、Shengting Zhang、Kanak Kanti Majumdar、Vikash Srivastava、Samiran Saha

  DOI：10.1016/j.bmcl.2010.10.030

  日期：2010.12

  A novel series of quinolinone-based adenosine A(2B) receptor antagonists was identified via high throughput screening of an encoded combinatorial compound collection. Synthesis and assay of a series of analogs highlighted essential structural features of the initial hit. Optimization resulted in an A2B antagonist (2i) which exhibited potent activity in a cAMP accumulation assay (5.1 nM) and an IL-8 release assay (0.4 nM). (C) 2010 Elsevier Ltd. All rights reserved.